Drug Type Small molecule drug |
Synonyms 康美纳, 酒石酸泰贝西利, BPI 16350 + [1] |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC28H32F2N8 |
InChIKeyXOJPAVACYRFOBK-GOSISDBHSA-N |
CAS Registry2397678-18-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | Phase 3 | CN | 25 May 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 17 Jul 2019 |
NCT03791112 (ASCO2023) Manual | Phase 1 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | HR Positive | 70 | qjwrzwxmyc(jhwmgzflca) = txopxtzapr jsqajfvser (kyjmnpoiiq ) View more | Positive | 31 May 2023 | |
qjwrzwxmyc(jhwmgzflca) = kkknftflzu jsqajfvser (kyjmnpoiiq ) View more |